Physician profile
Mark A Hill
NPI 1053354084
$36,939.02
in general payments reported to CMS, 2019-2025
66 companies · $5,254 in 2025
The $5,254 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,430 · 2021: $4,409 · 2022: $3,294 · 2023: $5,783 · 2024: $4,595 · 2025: $5,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,248.94 |
| Education | $383.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $7,240.97 | 2019-2023 | Sublocade |
| Astrazeneca Pharmaceuticals Lp | $5,188.00 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $2,454.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $2,118.84 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Viiv Healthcare Company | $2,074.53 | 2022-2025 | Dovato, Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,062.89 | 2019-2025 | Jardiance, Synjardy |
| Gilead Sciences, INC. | $1,971.83 | 2019-2025 | Biktarvy, Yeztugo, Sunlenca |
| Abbvie INC. | $1,315.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,269.28 | 2021-2025 | Dupixent |
| Novo Nordisk INC | $988.12 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $976.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Genzyme Corporation | $737.76 | 2021-2025 | |
| Shield Therapeutics INC | $707.41 | 2022-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $572.88 | 2019-2022 | |
| Amarin Pharma, INC. | $572.38 | 2019-2022 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.